{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:34:27Z","timestamp":1769852067184,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.anai.2018.02.017","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T13:21:54Z","timestamp":1519651314000},"page":"670-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-4418","authenticated-orcid":false,"given":"Merin","family":"Kuruvilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.02.017_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.017_bib0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.iac.2007.07.009","article-title":"Dermatologic manifestations of the hypereosinophilic syndromes","volume":"27","author":"Leiferman","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2018.02.017_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00062752-199905000-00007","article-title":"Interleukin-5 and the regulation of eosinophil production","volume":"6","author":"Roboz","year":"1999","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.anai.2018.02.017_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.017_bib0030","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.017_bib0035","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.017_bib0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.017_bib0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.017_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.anai.2018.02.017_bib0055","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti\u2013interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618301443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618301443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:20:35Z","timestamp":1761052835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618301443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1081120618301443"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.017","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}